These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 10685750

  • 1. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
    Mönkemüller KE, Call SA, Lazenby AJ, Wilcox CM.
    Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
    [Abstract] [Full Text] [Related]

  • 2. Gastroduodenal opportunistic infections and dyspepsia in HIV-infected patients in the era of Highly Active Antiretroviral Therapy.
    Werneck-Silva AL, Prado IB.
    J Gastroenterol Hepatol; 2009 Jan; 24(1):135-9. PubMed ID: 19054257
    [Abstract] [Full Text] [Related]

  • 3. Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy.
    Nkuize M, De Wit S, Muls V, Arvanitakis M, Buset M.
    HIV Med; 2010 Jul 01; 11(6):412-7. PubMed ID: 20146733
    [Abstract] [Full Text] [Related]

  • 4. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E.
    Parassitologia; 2004 Jun 01; 46(1-2):89-93. PubMed ID: 15305694
    [Abstract] [Full Text] [Related]

  • 5. Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy.
    Mönkemüller KE, Lazenby AJ, Lee DH, Loudon R, Wilcox CM.
    Dig Dis Sci; 2005 Feb 01; 50(2):230-4. PubMed ID: 15745077
    [Abstract] [Full Text] [Related]

  • 6. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM, Araneta MR, Deville JG, Spector SA.
    Clin Infect Dis; 2004 Sep 01; 39(5):725-31. PubMed ID: 15356789
    [Abstract] [Full Text] [Related]

  • 7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 01; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 8. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.
    Nicolatou-Galitis O, Velegraki A, Paikos S, Economopoulou P, Stefaniotis T, Papanikolaou IS, Kordossis T.
    Oral Dis; 2004 May 01; 10(3):145-50. PubMed ID: 15089923
    [Abstract] [Full Text] [Related]

  • 9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dyspepsia in HIV-infected patients under highly active antiretroviral therapy.
    Werneck-Silva AL, Prado IB.
    J Gastroenterol Hepatol; 2007 Nov 15; 22(11):1712-6. PubMed ID: 17559368
    [Abstract] [Full Text] [Related]

  • 13. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Oct 13; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 15. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ, Gazzard BG, Easterbrook PJ.
    J Infect; 2001 Feb 13; 42(2):134-9. PubMed ID: 11531320
    [Abstract] [Full Text] [Related]

  • 16. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX.
    Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013
    [Abstract] [Full Text] [Related]

  • 19. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL, Vale DA, Magalhães MH.
    J Oral Pathol Med; 2009 Jul 20; 38(6):489-94. PubMed ID: 19453845
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.